Member Info for daveycaferacer

https://www.hutch-med.com/hutchmed-completes-rolling-submission-of-nda-to-u-s-fda-for-surufatinib-for-the-treatment-of-advanced-nets/

HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that it completed the rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumors (“NETs”).

Great news! Possibly an RNS tomorrow on this...........

I know these research notes are paid for by the Company but Trinity Delta do spend quite some time explaining how they come to their valuation (DCF sum of the parts). Here's their comment from the 30th March:-

The first product wave is embarking on pivotal global studies, with the next wave progressing
into proof-of-concept trials. Ahead of these important value-inflection points, we
value HUTCHMED at $6.27bn (£4.83bn), equivalent to $43.10/ADS or 663p/share.

tacly, I agree on your point about cash, and I also hope you are wrong and we get an Asian listing!

Great buying opportunity at this price, I still firmly believe the Company is worth a lot more than $4bn given the huge late stage pipeline and revenue visibility going forward. We've had so much progress in the past 3 or 4 years that should have resulted in material valuation uplifts I'm still mystified as to what more the Company can do to change perception in the market, apart from keep on delivering....

first one I missed in 7 years thanks to my useless Broker who failed to provide me the credentials! I doubt whether that type of information would have been provided in an AGM format Bob, but we do know it is the Company's intention to have an Asian Listing

Under the 2021 Guidance section on page 56 of the recently updated Corporate Presentation it states "Continue to monitor market conditions for listings on other stock exchanges such as Hong Kong &Shanghai"

thx Jatw, I had the link and the PIN number but my broker should have provided a UserID and Password. First one missed in 7 years but I will be attending next year, hopefully in person, wherever the meeting happens to be!

I'm disappointed that today's AGM is the first I've missed in the last 7 years due to my somewhat inept Broker not providing the requested UserID and Password for the session. If anyone else attends please post anything interesting. I find Christian's presentation session most useful and there are always some interesting questions that arise at that point. I look forward to attending future meetings in person.

I am not sure on the significance of that johnam, but it doesn't surprise me that the market hasn't reacted, it didn't even react when we had our first ever approval in China. I'm at a loss as to what the Company needs to do to get an uplift in the valuation. Maybe delivering increased oncology revs will do the trick but the market seems asleep with regards to Hutchmed.

In addition to their note on the 5th March TD have released a subsequent note on the 30th March

https://www.trinitydelta.org/wp-content/uploads/2021/03/HUTCHMED-Outlook-210330.pdf

amones, it has also intrigued me that the volume increases substantially immediately prior to material news.. Savo in China of course is another one that should happen shortly, but I think Surufatinib approval in the U.S, possibly this year should be a major event.

LongOdds, I agree and have made the point many times over the years that merely having the word China in the Companies name was not a good idea, especially given the global ambitions. At least that has been put to bed.

It's interesting that a Company called Modern Chinese Medicine which shortens its name for every day use to Modern Chi-Med listed on the Hang Seng in January. It seems timely (or maybe part of the reason!) that Chi Med should be re-named HUTCHMED, particularly if a HK listing is forthcoming.

au contraire!! The cost of employing a CRO and the associated costs of running clinical trials is extremely significant. The later the Phase the higher the costs....

"Anyway. Am I too late for my free shares?"

No, if you were on the register at the Record date back in October you are entitled to Accustem shares, wherever they are listed.

This Company's its investor relations management is one of the worst I've seen, probably not helped by a hapless House Broker and Advisor. They have great assets and are great scientists but they really do need to get better advisors and sort out clear communication. They are not an AIM lifestyle business conducted for the benefit of the senior management and Directors, they are supposed to be a Main Listed Company and need to start behaving like one.

"Anyway. Am I too late for my free shares?"

Yes, if you were on the register at the Record date back in October.

This Company's its investor relations management is one of the worst I've seen, probably not helped by a hapless House Broker and Advisor. They have great assets and are great scientists but they really do need to get better advisors and sort out clear communication. They are not an AIM lifestyle business conducted for the benefit of the senior management and Directors, they are supposed to be a Main Listed Company and need to start behaving like one.

There may be a $4 price floor but they haven't stated how many shares will be issued with an American listing.

You cannot just say you will list in London then not mention it ever again.....

"and I don't see anything confusing or ambiguous..."

I disagree, they should have also stated clearly they no longer intend to list in London, if that is indeed the case. The reason I say that is they originally said they would list in London so if they no longer intend to they need to state it.

The most recent RNS on Accustem has caused confusion because it implied there would not be a listing in London as it was not mentioned. Appalling ambiguous communications by the Co's Nominated Advisor. I await their response of my request for clarification.

Sometimes charts can be useful with highly traded shares but not in this case, with a very large pool of stock tightly held and relatively low volumes traded. I agree with you Jatw and I think the valuation of Hutch-Med will play out long term based on pure fundamentals, P/S, P/E etc etc. I also think the market will have a different attitude once the company becomes cashflow positive in 2024/2025.